This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giaccone, G. Search for Related Content PubMed PubMed Citation Articles by Giaccone, G. Social Bookmarking                            What's this?

Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer

Giuseppe Giaccone

From the Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

Address reprint requests to G. Giaccone, MD, PhD, Division of Medical Oncology, Vrije Universiteit Medical Center, 1117 De Boelelaan, Amsterdam, The Netherlands; e-mail: g.giaccone{at}vumc.nl.

Remarkable developments in the systemic treatment of advanced non–small-cell lung cancer have taken place in the past few years. Targeted therapies have been largely employed in patients with far advanced disease, and some of them have demonstrated consistent activity in this setting. Epidermal growth factor receptor (EGFR) inhibitors cause dramatic response in approximately 10% of white patients who had received prior chemotherapy. Responses are higher in Asians. These findings are at least partly caused by the substantially higher incidence of EGFR mutations in Asians compared with whites. Studies of EGFR inhibitors in combination chemotherapy in front-line therapy of advanced non–small-cell lung cancer have, however, failed to improve survival, and better understanding of interactions between chemotherapeutic agents and EGFR inhibitors will be essential in the development of more effective strategies.

Author's disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. A. Hirschowitz and J. R. Yannelli Immunotherapy for Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 224 - 232. [Abstract] [Full Text] [PDF]

				O. J. Finn Cancer Immunology N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715. [Full Text] [PDF]

				A. F Gazdar EGFR Signaling Pathway Deregulation in Lung Cancer and Its Clinical Significance Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 85 - 89. [Abstract] [Full Text] [PDF]

				T. M. Gilmer, L. Cable, K. Alligood, D. Rusnak, G. Spehar, K. T. Gallagher, E. Woldu, H. L. Carter, A. T. Truesdale, L. Shewchuk, et al. Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib Cancer Res., January 15, 2008; 68(2): 571 - 579. [Abstract] [Full Text] [PDF]

				M. Loprevite, M. Tiseo, M. Chiaramondia, M. Capelletti, C. Bozzetti, B. Bortesi, N. Naldi, R. Nizzoli, P. Dadati, A. Kunkl, et al. Buccal Mucosa Cells as In vivo Model to Evaluate Gefitinib Activity in Patients with Advanced Non Small Cell Lung Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6518 - 6526. [Abstract] [Full Text] [PDF]

				M. V. Karamouzis, J. R. Grandis, and A. Argiris Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas JAMA, July 4, 2007; 298(1): 70 - 82. [Abstract] [Full Text] [PDF]

				C. Gridelli, M. A. Bareschino, C. Schettino, A. Rossi, P. Maione, and F. Ciardiello Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development Oncologist, July 1, 2007; 12(7): 840 - 849. [Abstract] [Full Text] [PDF]

				J.-D. Lay, C.-C. Hong, J.-S. Huang, Y.-Y. Yang, C.-Y. Pao, C.-H. Liu, Y.-P. Lai, G.-M. Lai, A.-L. Cheng, I.-J. Su, et al. Sulfasalazine Suppresses Drug Resistance and Invasiveness of Lung Adenocarcinoma Cells Expressing AXL Cancer Res., April 15, 2007; 67(8): 3878 - 3887. [Abstract] [Full Text] [PDF]

				F. Grossi, M. Aita, A. Follador, C. Defferrari, A. Brianti, G. Sinaccio, and O. Belvedere Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature Oncologist, April 1, 2007; 12(4): 451 - 464. [Abstract] [Full Text] [PDF]

				M. V. Karamouzis, P. A. Konstantinopoulos, and A. G. Papavassiliou The Activator Protein-1 Transcription Factor in Respiratory Epithelium Carcinogenesis Mol. Cancer Res., February 1, 2007; 5(2): 109 - 120. [Abstract] [Full Text] [PDF]

				M. Ono and M. Kuwano Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs Clin. Cancer Res., December 15, 2006; 12(24): 7242 - 7251. [Abstract] [Full Text] [PDF]

				B. Vischioni, J. J. Oudejans, W. Vos, J. A. Rodriguez, and G. Giaccone Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol. Cancer Ther., November 1, 2006; 5(11): 2905 - 2913. [Abstract] [Full Text] [PDF]

				F. Pastorino, C. Brignole, D. Di Paolo, B. Nico, A. Pezzolo, D. Marimpietri, G. Pagnan, F. Piccardi, M. Cilli, R. Longhi, et al. Targeting Liposomal Chemotherapy via Both Tumor Cell-Specific and Tumor Vasculature-Specific Ligands Potentiates Therapeutic Efficacy. Cancer Res., October 15, 2006; 66(20): 10073 - 10082. [Abstract] [Full Text] [PDF]

				G. Giaccone, M. Gallegos Ruiz, T. Le Chevalier, N. Thatcher, E. Smit, J. A. Rodriguez, P. Janne, D. Oulid-Aissa, and J.-C. Soria Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study. Clin. Cancer Res., October 15, 2006; 12(20): 6049 - 6055. [Abstract] [Full Text] [PDF]

				D. C. Birle and D. W. Hedley Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Mol. Cancer Ther., October 1, 2006; 5(10): 2494 - 2502. [Abstract] [Full Text] [PDF]

				S. Enatsu, A. Iwasaki, T. Shirakusa, M. Hamasaki, K. Nabeshima, H. Iwasaki, M. Kuroki, and M. Kuroki Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lung. Eur. J. Cardiothorac. Surg., June 1, 2006; 29(6): 891 - 895. [Abstract] [Full Text] [PDF]

				C.-K. Toh, F. Gao, W.-T. Lim, S.-S. Leong, K.-W. Fong, S.-P. Yap, A. A.L. Hsu, P. Eng, H.-N. Koong, A. Thirugnanam, et al. Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity J. Clin. Oncol., May 20, 2006; 24(15): 2245 - 2251. [Abstract] [Full Text] [PDF]

				S. Van Schaeybroeck, J. Kyula, D. M. Kelly, A. Karaiskou-McCaul, S. A. Stokesberry, E. Van Cutsem, D. B. Longley, and P. G. Johnston Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells Mol. Cancer Ther., May 1, 2006; 5(5): 1154 - 1165. [Abstract] [Full Text] [PDF]

				J. V. Alvarez, H. Greulich, W. R. Sellers, M. Meyerson, and D. A. Frank Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res., March 15, 2006; 66(6): 3162 - 3168. [Abstract] [Full Text] [PDF]

				C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689. [Abstract] [Full Text] [PDF]

				D. A. Reardon, J. A. Quinn, J. J. Vredenburgh, S. Gururangan, A. H. Friedman, A. Desjardins, S. Sathornsumetee, J. E. Herndon II, J. M. Dowell, R. E. McLendon, et al. Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma Clin. Cancer Res., February 1, 2006; 12(3): 860 - 868. [Abstract] [Full Text] [PDF]

				M. H Nelson and C. R Dolder Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors Ann. Pharmacother., February 1, 2006; 40(2): 261 - 269. [Abstract] [Full Text] [PDF]

				R. L. Yauch, T. Januario, D. A. Eberhard, G. Cavet, W. Zhu, L. Fu, T. Q. Pham, R. Soriano, J. Stinson, S. Seshagiri, et al. Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients Clin. Cancer Res., December 15, 2005; 11(24): 8686 - 8698. [Abstract] [Full Text] [PDF]

				D. H. Garfield Modern Treatment of Lung Cancer: CASE 2. Response to Erlotinib After Failure of Gefitinib in a Patient With Advanced Non-Small-Cell Lung Carcinoma J. Clin. Oncol., October 20, 2005; 23(30): 7738 - 7740. [Full Text] [PDF]

				S. E. Bates and T. Fojo Epidermal Growth Factor Receptor Inhibitors: A Moving Target? Clin. Cancer Res., October 15, 2005; 11(20): 7203 - 7205. [Full Text] [PDF]